Tesamorelin: A Growth Hormone-Releasing Factor Analog — Research Overview
Tesamorelin: A Growth Hormone-Releasing Factor Analog — Research Overview
Tesamorelin (also known by its development name TH9507) is a synthetic analog of the full-length 44-amino acid human growth hormone-releasing hormone (GHRH). It is distinguished from native GHRH by the addition of a trans-3-hexenoic acid group at the N-terminus, a modification designed to improve stability against enzymatic degradation while preserving full agonist activity at the GHRH receptor. Tesamorelin was developed by Theratechnologies Inc. and has been investigated in both preclinical and clinical research settings.
Mechanism of Action
Like CJC-1295, Tesamorelin acts as an agonist at the growth hormone-releasing hormone receptor (GHRHR) on anterior pituitary somatotrophs. Its binding triggers the Gs-protein/adenylyl cyclase/cAMP/PKA signaling cascade, leading to GH gene transcription, GH synthesis, and GH release.
The trans-3-hexenoic acid modification at the N-terminus provides protection against DPP-IV and other aminopeptidases that rapidly degrade native GHRH. However, unlike CJC-1295 with DAC, Tesamorelin does not bind to albumin, so its duration of action is shorter — producing a more physiological pulse-like GH response.
Tesamorelin preserves the natural pulsatility and feedback regulation of the GH/IGF-1 axis. Growth hormone release stimulated by Tesamorelin remains subject to somatostatin inhibition, meaning the body retains its normal regulatory control over GH levels.
Published Research
Clinical studies: Tesamorelin has been studied in randomized, double-blind, placebo-controlled clinical trials. In studies involving subjects with lipodystrophy, Tesamorelin administration was associated with increased GH and IGF-1 levels, along with measurable changes in body composition parameters compared to placebo (Falutz et al., New England Journal of Medicine, 2007; PMID: 17625124).
GH/IGF-1 axis: In clinical research, daily subcutaneous administration of Tesamorelin produced significant increases in both peak and integrated 24-hour GH secretion. IGF-1 levels rose in a dose-dependent manner while remaining within physiological ranges, suggesting preservation of the axis feedback mechanisms (Falutz et al., JCEM, 2008; PMID: 18728175).
Body composition: Multiple clinical studies have examined Tesamorelin's effects on body composition. Researchers observed reductions in visceral adipose tissue (VAT) as measured by CT scan in treated groups compared to placebo. These changes were associated with improvements in lipid profiles, including reductions in triglycerides (Falutz et al., NEJM, 2007; PMID: 17625124).
Cognitive research: Preliminary studies have also investigated Tesamorelin's effects on cognitive function in older adult populations. GH and IGF-1 are known to decline with age, and researchers have explored whether restoring these levels via GHRH analogs is associated with changes in cognitive biomarkers (Baker et al., Archives of Neurology, 2012; PMID: 22213582).
Purity and Quality Considerations
Tesamorelin is a 44-amino acid peptide with a non-standard N-terminal modification, making it one of the longer and more complex peptides to synthesize. Researchers should verify purity ≥98% by HPLC, confirm the correct molecular weight via mass spectrometry, and ensure the trans-3-hexenoic acid group is present and correctly attached. Learn more about purity testing methods and quality standards at CALM Peptides.
Available for Research
CALM Peptides offers research-grade Tesamorelin with third-party purity verification. Certificates of Analysis are available upon request. Browse all strength peptides or explore our full catalog.
Frequently Asked Questions
What is Tesamorelin?
Tesamorelin is a synthetic 44-amino acid analog of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus. It is studied for its ability to stimulate endogenous growth hormone secretion through the GHRH receptor.
How does Tesamorelin differ from CJC-1295?
Both are GHRH analogs, but they differ in structure and pharmacokinetics. Tesamorelin is a modified version of the full-length GHRH(1-44), while CJC-1295 is based on the truncated GHRH(1-29). CJC-1295 with DAC has a much longer half-life due to albumin binding.
Does Tesamorelin produce pulsatile GH release?
Yes. Unlike CJC-1295 with DAC, which produces sustained GH elevation, Tesamorelin produces a more physiological pulse-like GH response that remains subject to somatostatin feedback regulation.
What research models have been used to study Tesamorelin?
Tesamorelin has been studied in randomized placebo-controlled clinical trials examining body composition changes, GH/IGF-1 axis effects, and preliminary cognitive endpoints in older adult populations.
The information presented in this article is for educational and informational purposes only and is not intended as medical advice. Tesamorelin is sold as a research chemical for laboratory use only. It is not intended for human consumption, and should not be used to diagnose, treat, cure, or prevent any disease. All references to published research are provided for informational context. Consult qualified professionals for guidance related to any health condition.
For research use only. Not for human consumption.
Related Reading: What Are Peptides? · Strength & Performance Peptides · CJC-1295 Research Overview · Ipamorelin Research Overview · Quality & Purity Standards
The information presented in this article is for educational and informational purposes only and is not intended as medical advice. All products referenced are sold as research chemicals for laboratory use only. They are not intended for human consumption and should not be used to diagnose, treat, cure, or prevent any disease. All references to published research are provided for informational context. Consult qualified professionals for guidance related to any health condition.